The stock of Palisade Bio Inc (PALI) has seen a 9.58% increase in the past week, with a -7.83% drop in the past month, and a -1.32% decrease in the past quarter. The volatility ratio for the week is 7.21%, and the volatility levels for the past 30 days are at 5.82% for PALI. The simple moving average for the past 20 days is 0.32% for PALI’s stock, with a -59.85% simple moving average for the past 200 days.
Is It Worth Investing in Palisade Bio Inc (NASDAQ: PALI) Right Now?
PALI has 36-month beta value of 1.38. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PALI is 4.76M, and currently, short sellers hold a 4.79% ratio of that float. The average trading volume of PALI on June 24, 2025 was 288.63K shares.
PALI) stock’s latest price update
Palisade Bio Inc (NASDAQ: PALI) has seen a rise in its stock price by 523943 in relation to its previous close of 0.62. However, the company has experienced a 9.58% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-27 that Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “What This Means” segment discussing the topline Phase 1a data; Access here Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced positive topline results from its completed Phase 1 studies of PALI-2108, a novel, locally-activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D (PDE4 B/D) inhibitor being developed for fibrostenotic Crohn’s disease (FSCD) and moderate to severe ulcerative colitis (UC). Additionally, the Company announced the release of a Virtual Investor “What This Means” segment to discuss the topline data, which is now available here.
PALI Trading at -2.59% from the 50-Day Moving Average
After a stumble in the market that brought PALI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.66% of loss for the given period.
Stock Fundamentals for PALI
The total capital return value is set at -2.49. Equity return is now at value -170.72, with -126.10 for asset returns.
Based on Palisade Bio Inc (PALI), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -195.62. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1349.6.
Currently, EBITDA for the company is -14.86 million with net debt to EBITDA at 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.81.
Conclusion
To put it simply, Palisade Bio Inc (PALI) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
